Breast Cancer Expert Nancy Davidson Elected ASCO President for 2007-2008

Publication
Article
OncologyONCOLOGY Vol 20 No 7
Volume 20
Issue 7

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

In addition, Bruce J. Roth, MD, professor of medicine/urologic surgery at Vanderbilt-Ingram Cancer Center, was elected secretary-treasurer for the 2006-2009 term. Five new members were elected to the ASCO board of directors (Howard A. Burris III, MD, Waun Ki Hong, MD, FACP, DMSC, Thomas Marsland, MD, Gregory H. Reaman, MD, and Martine J. Piccart-Gebhart, MD, PHD) and two new members to the ASCO nominating committee (Edith Perez, MD, and Eric P. Winer, MD), all for 3‑year terms beginning in June 2006.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content